Literature DB >> 34587558

Dichoptic visual field mapping of suppression in exotropia with homonymous hemianopia.

John R Economides1, Jonathan C Horton2.   

Abstract

BACKGROUND: The purpose of this study was to investigate which portions of the visual scene are perceived by each eye in an exotropic subject with acquired hemianopia. The pattern of suppression is predictable from knowledge of how suppression scotomas are organized in exotropic subjects with intact visual fields.
METHODS: Dichoptic perimetry was performed by having a subject wear red/blue goggles while fixating a cross that was either red or blue. Red, blue, or purple spots were presented briefly at peripheral locations. The subject's identification of the spot color revealed which eye was perceptually engaged at any given location in the visual fields.
RESULTS: A 17-year-old female with a history of exotropia was evaluated after rupture of a right parietal arteriovenous malformation. Dichoptic perimetry showed a left homonymous hemianopia. All stimuli to the right of the right fovea's projection point were perceived via the right eye. Stimuli between the foveal projection points, which were separated horizontally by the 20° exotropia, were perceived by the left eye.
CONCLUSIONS: Perception of the visual scene is shared by the eyes in hemianopia and exotropia. Suppression occurs only in the peripheral temporal retina of the eye contralateral to the brain lesion, regardless of which eye is engaged in fixation. Although exotropia expands the binocular field of vision in hemianopia, it is probably not an adaptive response, even when it develops after hemianopia.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34587558      PMCID: PMC8665098          DOI: 10.1016/j.jaapos.2021.05.017

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  32 in total

1.  Does visual restitution training change absolute homonymous visual field defects? A fundus controlled study.

Authors:  J Reinhard; A Schreiber; U Schiefer; E Kasten; B A Sabel; S Kenkel; R Vonthein; S Trauzettel-Klosinski
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

Review 2.  Homonymous hemianopia and exotropia: an important management issue.

Authors:  G M Saleh; S Sivaprasad; C J Hammond
Journal:  Eye (Lond)       Date:  2006-03-17       Impact factor: 3.775

Review 3.  How useful is anomalous correspondence?

Authors:  V Herzau
Journal:  Eye (Lond)       Date:  1996       Impact factor: 3.775

4.  Suppression and retinal correspondence in intermittent exotropia.

Authors:  J Cooper; C D Record
Journal:  Br J Ophthalmol       Date:  1986-09       Impact factor: 4.638

5.  [Investigations on binocular visual fields in scotoma].

Authors:  V Herzau
Journal:  Doc Ophthalmol       Date:  1980-10-15       Impact factor: 2.379

6.  Mechanisms compensating for visual field restriction in adolescents with damage to the retro-geniculate visual system.

Authors:  L Jacobson; F Lennartsson; T Pansell; G Oqvist Seimyr; L Martin
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

7.  Impact of large angle horizontal strabismus on ability to obtain employment.

Authors:  D K Coats; E A Paysse; A J Towler; R L Dipboye
Journal:  Ophthalmology       Date:  2000-02       Impact factor: 12.079

8.  Etiology and Age Modifies Subjective Visual Function After Cerebral Hemispherectomy.

Authors:  Monica F Chen; Elana Meer; Federico G Velez; Monika Jones; Gary W Mathern; Stacy L Pineles
Journal:  J Child Neurol       Date:  2019-04-07       Impact factor: 1.987

9.  Visual Function 20 Years After Childhood Hemispherectomy for Intractable Epilepsy.

Authors:  Sian E Handley; Faraneh Vargha-Khadem; Richard J Bowman; Alki Liasis
Journal:  Am J Ophthalmol       Date:  2017-02-22       Impact factor: 5.258

10.  Management of strabismus with hemianopic visual field defects.

Authors:  Melanie van Waveren; Herbert Jägle; Dorothea Besch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.